Cargando…

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel

Bevacizumab plus weekly paclitaxel improves progression-free survival (PFS) in HER2-negative metastatic breast cancer (mBC), but its use has been questioned due to the absence of a predictive biomarker, lack of benefit in overall survival (OS) and increased toxicity. We examined the baseline tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendiola, Marta, Martínez-Marin, Virginia, Herranz, Jesús, Heredia, Victoria, Yébenes, Laura, Zamora, Pilar, Castelo, Beatriz, Pinto, Álvaro, Miguel, María, Díaz, Esther, Gámez, Angelo, Fresno, Juan Ángel, de Molina, Ana Ramírez, Hardisson, David, Espinosa, Enrique, Redondo, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029696/ https://www.ncbi.nlm.nih.gov/pubmed/26992213 http://dx.doi.org/10.18632/oncotarget.8128

Ejemplares similares

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

Comparison of Prognostic Gene Profiles Using qRT-PCR in Paraffin Samples: A Retrospective Study in Patients with Early Breast Cancer
por: Espinosa, Enrique, et al.
Publicado: (2009)

Angiogenesis-Related Gene Expression Profile with Independent Prognostic Value in Advanced Ovarian Carcinoma
por: Mendiola, Marta, et al.
Publicado: (2008)

Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2019)

High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease
por: Heredia-Soto, Victoria, et al.
Publicado: (2018)

Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma
por: Ruz-Caracuel, Ignacio, et al.
Publicado: (2021)

An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer
por: Sánchez-Navarro, Iker, et al.
Publicado: (2010)

The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation
por: Heredia-Soto, V., et al.
Publicado: (2020)

A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
por: Martin-Broto, Javier, et al.
Publicado: (2022)

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma
por: Bui, Nam, et al.
Publicado: (2018)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
por: Petitjean, Audrey, et al.
Publicado: (2019)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance
por: Fernández, Lara P., et al.
Publicado: (2018)

New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting
por: Cannita, Katia, et al.
Publicado: (2016)

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study
por: Ardavanis, Alexandros, et al.
Publicado: (2009)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
por: Nakamoto, Shogo, et al.
Publicado: (2021)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
por: Gámez-Pozo, Angelo, et al.
Publicado: (2014)

A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients
por: Coltelli, Luigi, et al.
Publicado: (2022)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer()()
por: Bahl, Amit, et al.
Publicado: (2022)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling
por: López-Janeiro, Álvaro, et al.
Publicado: (2021)

CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
por: Behrouzi, Roya, et al.
Publicado: (2023)

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer
por: Sugiyama, Toru, et al.
Publicado: (2017)

Severe skin toxicity due to weekly paclitaxel administration
por: Kate, Shruti, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o50onbd4rasupg3kd0h1vmosmf